In vitro changes in the proportion of protein-unbound-free propofol induced by valproate
- 38 Downloads
It has been reported that oral valproate (VPA) reduces the dose of propofol required for sedation. As a potential reason for this, it is considered that VPA displaces serum protein-bound propofol and increases the proportion of protein-unbound-free propofol. To examine this hypothesis, the present in vitro study investigated the influence of VPA on the proportion of protein-unbound-free propofol in human serum samples.
Serum samples were collected from 10 healthy volunteers, who were not taking any medication. VPA (final concentration: 0.05, 0.1 or 1 mg/mL) and propofol (final concentration: 1 or 5 µg/mL) were mixed with serum samples with normal (4.0 g/dL) or low (2.5 g/dL) albumin concentrations. Then, protein-unbound-free propofol was extracted from the samples, and its concentration was measured using high-performance liquid chromatography. We compared the proportion of protein-unbound-free propofol in each of the VPA-containing samples with that in serum samples without VPA (control).
In the serum samples with normal albumin concentrations, 1 mg/mL VPA significantly increased the proportion of protein-unbound-free propofol at 1 and 5 µg/mL propofol. Furthermore, in the serum samples with low albumin concentrations, the proportion of protein-unbound-free propofol was significantly increased by both 0.1 and 1 mg/mL VPA at propofol concentrations of 1 and 5 µg/mL.
VPA might increase the proportion of protein-unbound-free propofol in human serum via displacement reactions.
KeywordsAntiepileptic drugs Propofol Drug interactions Serum protein
The present study was supported by institutional funding of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and a Grant-in-Aid for Young Scientists (B) (24792214) from the Japan Society for Promotion of Science.
- 19.Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.CrossRefGoogle Scholar
- 20.American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(4 Suppl):1–50.Google Scholar
- 27.Gomez MJ, Santos Buelga D, Alonso AC, Garcia MJ, Dominguez-Gil A. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding. Eur J Drug Metab Pharmacokinet. 1991;3:239–42.Google Scholar